What is the history of Leber Hereditary Optic Neuropathy?

Leber Hereditary Optic Neuropathy (LHON) was first formally described by German ophthalmologist Theodor Leber in 1871, who identified the characteristic pattern of painless, rapid vision loss in young men. Since then, our understanding of Leber Hereditary Optic Neuropathy has evolved from a mysterious familial condition to the first disease recognized as being caused by a mutation in mitochondrial DNA (mtDNA).

Who first discovered Leber Hereditary Optic Neuropathy?

Theodor Leber, a professor of ophthalmology at the University of Göttingen, published his landmark paper in 1871 titled "Ueber hereditäre und congenital-angelegte Sehnervenleiden." He observed a peculiar trend: the condition predominantly affected young males and was transmitted through the maternal line. For nearly a century, researchers struggled to explain why this form of Leber Hereditary Optic Neuropathy skipped generations or appeared sporadically, as the mechanisms of mitochondrial inheritance were not yet understood.

How has our understanding of Leber Hereditary Optic Neuropathy evolved?

The most significant shift occurred in 1988, when Douglas Wallace and his team discovered that Leber Hereditary Optic Neuropathy is caused by point mutations in mitochondrial DNA. This shifted the medical perspective from viewing it as a standard Mendelian genetic disorder to a complex mitochondrial disease. Modern genetic screening now identifies three primary mtDNA mutations (m.11778G>A, m.3460G>A, and m.14484T>C) responsible for approximately 90% of cases.

What are the major historical milestones in treatment and advocacy?

Historically, patients were often misdiagnosed with multiple sclerosis or optic neuritis. Today, our approach to Leber Hereditary Optic Neuropathy focuses on managing symptoms and developing gene therapies. Key milestones include:

• 1988: Identification of the first mitochondrial mutation linked to the disease.


• 2015: Approval of Idebenone in the European Union, the first medication specifically indicated for Leber Hereditary Optic Neuropathy.


• 2020s: The emergence of gene therapy clinical trials aimed at correcting the underlying mitochondrial defect.

How has the community shaped the history of this disease?

As part of the DiseaseMaps.org community, 57 people with Leber Hereditary Optic Neuropathy have shared their lived experiences, helping to bridge the gap between clinical data and the human reality of vision loss. This advocacy has been crucial in shifting research priorities toward patient-centered outcomes and faster diagnostic protocols.

Next steps

• Consult with a neuro-ophthalmologist to confirm your diagnosis and discuss the latest clinical trial opportunities.


• Connect with the 57 members on DiseaseMaps.org to share resources and personal experiences.


• Undergo formal genetic counseling to understand the inheritance patterns and risks for family members.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Leber Hereditary Optic Neuropathy.


• Orphanet: Rare disease database entry for Leber Hereditary Optic Neuropathy.


• OMIM (Online Mendelian Inheritance in Man): Entry #535000.


• Leber Hereditary Optic Neuropathy Society (LHON.org).